Loading…
Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor
Background Therapy‐related leukemia is a well‐recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors. Aims Hematologic toxicities inclu...
Saved in:
| Published in: | Cancer reports 2020-10, Vol.3 (5), p.e1282-n/a |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4432-b6808770159f1652bddc9e1b9195359f8cf447e8a7b0a2cfeaca05b58a8c528a3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4432-b6808770159f1652bddc9e1b9195359f8cf447e8a7b0a2cfeaca05b58a8c528a3 |
| container_end_page | n/a |
| container_issue | 5 |
| container_start_page | e1282 |
| container_title | Cancer reports |
| container_volume | 3 |
| creator | Kucukyurt, Selin Yagiz Ozogul, Yeliz Ercaliskan, Abdulkadir Kabasakal, Levent Eskazan, Ahmet Emre |
| description | Background
Therapy‐related leukemia is a well‐recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors.
Aims
Hematologic toxicities including late‐onset myeloid neoplasms have been reported after PRRT; however, therapy‐related chronic myeloid leukemia (TR‐CML) following PRRT is a relatively rare entity.
Methods
We present a 64‐year‐old male who received PRRT for pancreas neuroendocrine tumor and then developed TR‐CML 60 months after the initiation of PRRT. The patient responded well to imatinib therapy.
Results
Patients with TR‐CML generally have similar tyrosine kinase inhibitor responses and outcomes when compared to de novo cases.
Conclusions
The physicians should be aware of the short‐ and long‐term hematologic toxicities of PRRT including TR‐CML, and careful monitoring is mandatory in this group of patients. |
| doi_str_mv | 10.1002/cnr2.1282 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7941585</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3090225110</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4432-b6808770159f1652bddc9e1b9195359f8cf447e8a7b0a2cfeaca05b58a8c528a3</originalsourceid><addsrcrecordid>eNp1kU1rFTEUhgdRbKld-Ack4EYXt83nnWQjyMUvKApS1yGTOdObmknGMzMtd-fejb_RX2Kmt5YquEp4z8PDObxV9ZTRE0YpP_UJ-Qnjmj-oDrmqxUoLqR_e-x9Ux-N4SSllei24EY-rA8G1WVPDDqsf51tAN-x-ff-JEN0ELfFbzCl40u8g5tCSCPNX6IMjIRFHBjcFSBNB8BCuQrogAwxTaOEmGaaMBF0bcpp9XNJp7yddGQwueYQi8CTBjBlSmz2GVKi5z_iketS5OMLx7XtUfXn75nzzfnX26d2HzeuzlZdS8FWz1lTXNWXKdGyteNO23gBrDDNKlEz7TsoatKsb6rjvwHlHVaO0015x7cRR9WrvHeamh9aXc9BFO2DoHe5sdsH-PUlhay_yla2NZEqrInhxK8D8bYZxsn0YPcToEuR5tFxKaqg0akGf_4Ne5hlTOc-KwnCuGKOFermnPOZxROjulmHULi3bpWW7tFzYZ_e3vyP_dFqA0z1wHSLs_m-ym4-f-Y3yN2l4tlw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3090225110</pqid></control><display><type>article</type><title>Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor</title><source>Wiley</source><source>Publicly Available Content Database</source><source>PubMed</source><source>Coronavirus Research Database</source><creator>Kucukyurt, Selin ; Yagiz Ozogul, Yeliz ; Ercaliskan, Abdulkadir ; Kabasakal, Levent ; Eskazan, Ahmet Emre</creator><creatorcontrib>Kucukyurt, Selin ; Yagiz Ozogul, Yeliz ; Ercaliskan, Abdulkadir ; Kabasakal, Levent ; Eskazan, Ahmet Emre</creatorcontrib><description>Background
Therapy‐related leukemia is a well‐recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors.
Aims
Hematologic toxicities including late‐onset myeloid neoplasms have been reported after PRRT; however, therapy‐related chronic myeloid leukemia (TR‐CML) following PRRT is a relatively rare entity.
Methods
We present a 64‐year‐old male who received PRRT for pancreas neuroendocrine tumor and then developed TR‐CML 60 months after the initiation of PRRT. The patient responded well to imatinib therapy.
Results
Patients with TR‐CML generally have similar tyrosine kinase inhibitor responses and outcomes when compared to de novo cases.
Conclusions
The physicians should be aware of the short‐ and long‐term hematologic toxicities of PRRT including TR‐CML, and careful monitoring is mandatory in this group of patients.</description><identifier>ISSN: 2573-8348</identifier><identifier>EISSN: 2573-8348</identifier><identifier>DOI: 10.1002/cnr2.1282</identifier><identifier>PMID: 32896091</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Blood platelets ; Bone marrow ; Case Report ; Case Reports ; Chemoembolization ; Chemotherapy ; Chromosomes ; chronic myeloid leukemia ; Hemoglobin ; Kinases ; Leukemia ; Leukocytes ; Medical prognosis ; neuroendocrine tumor ; Neuroendocrine tumors ; Neutrophils ; Patients ; peptide receptor radionuclide therapy ; Peptides ; Radiation therapy ; therapy‐related leukemia ; Toxicity ; tyrosine kinase inhibitor</subject><ispartof>Cancer reports, 2020-10, Vol.3 (5), p.e1282-n/a</ispartof><rights>2020 The Authors. published by Wiley Periodicals LLC.</rights><rights>2020 The Authors. Cancer Reports published by Wiley Periodicals LLC.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4432-b6808770159f1652bddc9e1b9195359f8cf447e8a7b0a2cfeaca05b58a8c528a3</citedby><cites>FETCH-LOGICAL-c4432-b6808770159f1652bddc9e1b9195359f8cf447e8a7b0a2cfeaca05b58a8c528a3</cites><orcidid>0000-0002-1795-5773 ; 0000-0002-4050-1972 ; 0000-0001-9568-0894 ; 0000-0001-6983-8504 ; 0000-0001-8742-3388</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941585/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3090225110?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32896091$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kucukyurt, Selin</creatorcontrib><creatorcontrib>Yagiz Ozogul, Yeliz</creatorcontrib><creatorcontrib>Ercaliskan, Abdulkadir</creatorcontrib><creatorcontrib>Kabasakal, Levent</creatorcontrib><creatorcontrib>Eskazan, Ahmet Emre</creatorcontrib><title>Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor</title><title>Cancer reports</title><addtitle>Cancer Rep (Hoboken)</addtitle><description>Background
Therapy‐related leukemia is a well‐recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors.
Aims
Hematologic toxicities including late‐onset myeloid neoplasms have been reported after PRRT; however, therapy‐related chronic myeloid leukemia (TR‐CML) following PRRT is a relatively rare entity.
Methods
We present a 64‐year‐old male who received PRRT for pancreas neuroendocrine tumor and then developed TR‐CML 60 months after the initiation of PRRT. The patient responded well to imatinib therapy.
Results
Patients with TR‐CML generally have similar tyrosine kinase inhibitor responses and outcomes when compared to de novo cases.
Conclusions
The physicians should be aware of the short‐ and long‐term hematologic toxicities of PRRT including TR‐CML, and careful monitoring is mandatory in this group of patients.</description><subject>Blood platelets</subject><subject>Bone marrow</subject><subject>Case Report</subject><subject>Case Reports</subject><subject>Chemoembolization</subject><subject>Chemotherapy</subject><subject>Chromosomes</subject><subject>chronic myeloid leukemia</subject><subject>Hemoglobin</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Leukocytes</subject><subject>Medical prognosis</subject><subject>neuroendocrine tumor</subject><subject>Neuroendocrine tumors</subject><subject>Neutrophils</subject><subject>Patients</subject><subject>peptide receptor radionuclide therapy</subject><subject>Peptides</subject><subject>Radiation therapy</subject><subject>therapy‐related leukemia</subject><subject>Toxicity</subject><subject>tyrosine kinase inhibitor</subject><issn>2573-8348</issn><issn>2573-8348</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><recordid>eNp1kU1rFTEUhgdRbKld-Ack4EYXt83nnWQjyMUvKApS1yGTOdObmknGMzMtd-fejb_RX2Kmt5YquEp4z8PDObxV9ZTRE0YpP_UJ-Qnjmj-oDrmqxUoLqR_e-x9Ux-N4SSllei24EY-rA8G1WVPDDqsf51tAN-x-ff-JEN0ELfFbzCl40u8g5tCSCPNX6IMjIRFHBjcFSBNB8BCuQrogAwxTaOEmGaaMBF0bcpp9XNJp7yddGQwueYQi8CTBjBlSmz2GVKi5z_iketS5OMLx7XtUfXn75nzzfnX26d2HzeuzlZdS8FWz1lTXNWXKdGyteNO23gBrDDNKlEz7TsoatKsb6rjvwHlHVaO0015x7cRR9WrvHeamh9aXc9BFO2DoHe5sdsH-PUlhay_yla2NZEqrInhxK8D8bYZxsn0YPcToEuR5tFxKaqg0akGf_4Ne5hlTOc-KwnCuGKOFermnPOZxROjulmHULi3bpWW7tFzYZ_e3vyP_dFqA0z1wHSLs_m-ym4-f-Y3yN2l4tlw</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Kucukyurt, Selin</creator><creator>Yagiz Ozogul, Yeliz</creator><creator>Ercaliskan, Abdulkadir</creator><creator>Kabasakal, Levent</creator><creator>Eskazan, Ahmet Emre</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1795-5773</orcidid><orcidid>https://orcid.org/0000-0002-4050-1972</orcidid><orcidid>https://orcid.org/0000-0001-9568-0894</orcidid><orcidid>https://orcid.org/0000-0001-6983-8504</orcidid><orcidid>https://orcid.org/0000-0001-8742-3388</orcidid></search><sort><creationdate>202010</creationdate><title>Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor</title><author>Kucukyurt, Selin ; Yagiz Ozogul, Yeliz ; Ercaliskan, Abdulkadir ; Kabasakal, Levent ; Eskazan, Ahmet Emre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4432-b6808770159f1652bddc9e1b9195359f8cf447e8a7b0a2cfeaca05b58a8c528a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Blood platelets</topic><topic>Bone marrow</topic><topic>Case Report</topic><topic>Case Reports</topic><topic>Chemoembolization</topic><topic>Chemotherapy</topic><topic>Chromosomes</topic><topic>chronic myeloid leukemia</topic><topic>Hemoglobin</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Leukocytes</topic><topic>Medical prognosis</topic><topic>neuroendocrine tumor</topic><topic>Neuroendocrine tumors</topic><topic>Neutrophils</topic><topic>Patients</topic><topic>peptide receptor radionuclide therapy</topic><topic>Peptides</topic><topic>Radiation therapy</topic><topic>therapy‐related leukemia</topic><topic>Toxicity</topic><topic>tyrosine kinase inhibitor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kucukyurt, Selin</creatorcontrib><creatorcontrib>Yagiz Ozogul, Yeliz</creatorcontrib><creatorcontrib>Ercaliskan, Abdulkadir</creatorcontrib><creatorcontrib>Kabasakal, Levent</creatorcontrib><creatorcontrib>Eskazan, Ahmet Emre</creatorcontrib><collection>Wiley-Blackwell Open Access Collection</collection><collection>Wiley Free Archive</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kucukyurt, Selin</au><au>Yagiz Ozogul, Yeliz</au><au>Ercaliskan, Abdulkadir</au><au>Kabasakal, Levent</au><au>Eskazan, Ahmet Emre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor</atitle><jtitle>Cancer reports</jtitle><addtitle>Cancer Rep (Hoboken)</addtitle><date>2020-10</date><risdate>2020</risdate><volume>3</volume><issue>5</issue><spage>e1282</spage><epage>n/a</epage><pages>e1282-n/a</pages><issn>2573-8348</issn><eissn>2573-8348</eissn><abstract>Background
Therapy‐related leukemia is a well‐recognized clinical syndrome. Peptide receptor radionuclide therapy (PRRT) is a modern therapeutic approach using radionuclide combined with somatostatin analog peptide for inoperable or metastatic neuroendocrine tumors.
Aims
Hematologic toxicities including late‐onset myeloid neoplasms have been reported after PRRT; however, therapy‐related chronic myeloid leukemia (TR‐CML) following PRRT is a relatively rare entity.
Methods
We present a 64‐year‐old male who received PRRT for pancreas neuroendocrine tumor and then developed TR‐CML 60 months after the initiation of PRRT. The patient responded well to imatinib therapy.
Results
Patients with TR‐CML generally have similar tyrosine kinase inhibitor responses and outcomes when compared to de novo cases.
Conclusions
The physicians should be aware of the short‐ and long‐term hematologic toxicities of PRRT including TR‐CML, and careful monitoring is mandatory in this group of patients.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>32896091</pmid><doi>10.1002/cnr2.1282</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-1795-5773</orcidid><orcidid>https://orcid.org/0000-0002-4050-1972</orcidid><orcidid>https://orcid.org/0000-0001-9568-0894</orcidid><orcidid>https://orcid.org/0000-0001-6983-8504</orcidid><orcidid>https://orcid.org/0000-0001-8742-3388</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2573-8348 |
| ispartof | Cancer reports, 2020-10, Vol.3 (5), p.e1282-n/a |
| issn | 2573-8348 2573-8348 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7941585 |
| source | Wiley; Publicly Available Content Database; PubMed; Coronavirus Research Database |
| subjects | Blood platelets Bone marrow Case Report Case Reports Chemoembolization Chemotherapy Chromosomes chronic myeloid leukemia Hemoglobin Kinases Leukemia Leukocytes Medical prognosis neuroendocrine tumor Neuroendocrine tumors Neutrophils Patients peptide receptor radionuclide therapy Peptides Radiation therapy therapy‐related leukemia Toxicity tyrosine kinase inhibitor |
| title | Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A00%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapy%E2%80%90related%20chronic%20myeloid%20leukemia%20in%20a%20patient%20receiving%20peptide%20receptor%20radionuclide%20therapy%20for%20pancreatic%20neuroendocrine%20tumor&rft.jtitle=Cancer%20reports&rft.au=Kucukyurt,%20Selin&rft.date=2020-10&rft.volume=3&rft.issue=5&rft.spage=e1282&rft.epage=n/a&rft.pages=e1282-n/a&rft.issn=2573-8348&rft.eissn=2573-8348&rft_id=info:doi/10.1002/cnr2.1282&rft_dat=%3Cproquest_pubme%3E3090225110%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4432-b6808770159f1652bddc9e1b9195359f8cf447e8a7b0a2cfeaca05b58a8c528a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3090225110&rft_id=info:pmid/32896091&rfr_iscdi=true |